Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

{{article.zuoZheEn}}

PDF(1086 KB)
PDF(1086 KB)
Front. Med. ›› 2022, Vol. 16 ›› Issue (1) : 139-149. DOI: 10.1007/s11684-021-0835-8
RESEARCH ARTICLE

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2022, 16(1): 139‒149 https://doi.org/10.1007/s11684-021-0835-8

References

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
Share on Mendeley
PDF(1086 KB)

Accesses

Citations

Detail

Sections
Recommended

/